Financial Shenanigans

The Forensic Verdict

Cigna's accounting itself looks defensible — there is no restatement, no auditor change, no disclosed material weakness, and PwC has audited the company since 1983 — but a stack of operating-conduct and presentation flags push the forensic risk grade to Elevated. The two issues that move the grade are (i) a $172 million False Claims Act settlement and Corporate Integrity Agreement covering Medicare Advantage diagnosis coding for 2014–2019, and a fresh class-action complaint (Bernstein Litowitz, Feb 17, 2026) alleging that Express Scripts diverted billions of drug-manufacturer rebates to a Swiss affiliate, Ascent Health Services, which the FTC has now forced Cigna to redomicile to the U.S.; and (ii) an "adjusted income from operations" series that prints almost suspiciously smooth ($7.45B → $7.74B → $8.01B) while GAAP shareholders' net income swings violently ($5.16B → $3.43B → $5.96B), with 50% of CEO bonus tied to the smoothed metric. The receivables-driven cash-flow timing — Cigna runs an ongoing accounts-receivable factoring facility and explicitly cites it as a CFO swing factor — and a soft asset base where goodwill plus intangibles are still 46.5% of total assets are the supporting concerns. The single data point that would most change the grade: an SEC enforcement filing or a 10-K/A on rebate or revenue accounting tied to the Ascent litigation.

13-Shenanigan Scorecard

The shape of risk is consistent across the scorecard: nothing in the audited GAAP statements is broken, but the stories around the statements — pharmacy rebates routed through Ascent, Medicare Advantage chart-review codes, $4.3B 2024 swing between adjusted and GAAP earnings, AR factoring as a cash-flow lever — are where economic substance is harder to verify than reported income suggests. Treat the report as elevated risk, not clean.

Breeding Ground

The governance breeding ground is moderate. Cigna has strong on-paper independence (all directors except Cordani are independent, fully independent audit and compensation committees, lead independent director), and the audit committee has two designated audit-committee financial experts. Offsetting this, the CEO and Chairman role are still combined under David Cordani — and the announced 2026 transition keeps Cordani on as Executive Chair while Brian Evanko (President/COO since March 2025) becomes CEO, leaving founder-style influence intact through the leadership change. Compensation is heavily tied to non-GAAP measures: 50% of the 2025 EIP bonus weighting is on "adjusted income from operations," a metric the company also uses for the long-term Strategic Performance Share program. The People Resources Committee explicitly approved downward adjustments to 2024 and 2025 adjusted income to "ensure year-over-year comparability" after the HCSC divestiture — a legitimate practice, but one that should be watched because it gives the committee discretion to recalibrate the bar.

The breeding ground reads as "elevated structural permission, but live independent oversight." Two factors do real work: pay tied to non-GAAP smoothness (which is a soft incentive to keep adjustments large and definitions stable in management's favor) and the Ascent affiliate, which by its existence creates a related-party economic loop that plaintiffs and regulators are actively probing.

Earnings Quality

GAAP earnings have been volatile, adjusted earnings have not. That alone is the most informative signal in the file.

Adjusted income from operations rose 4% in 2024 and 4% in 2025. GAAP shareholders' net income fell 34% in 2024 and rose 73% in 2025. The bridge: a $2.5B VillageMD equity impairment, $1.7B/year of acquired-intangible amortization, an HCSC-related goodwill impairment in 2023 (-$1.5B) and gain in 2025 (+$13M), and a $749M strategic optimization charge in 2025. None of these are improperly excluded individually, but the recurring presence of "special items" — and the smoothness of the resulting adjusted line — is a metric-hygiene yellow rather than a clean pass.

Excluding 2018–2019 (Express Scripts acquisition close and first full-year integration), receivables have outgrown revenue in five of six years. In 2024, receivables grew 36.7% on revenue growth of 26.6%, with $24.2B of receivables at year-end. In 2025, receivables grew 18.7% on revenue growth of 11.2%, lifting DSO from 35.8 to 38.2 days. Management attributes the build to client onboardings in Evernorth and to the timing of factoring-facility settlements. The pattern does not by itself indicate revenue pulled forward — Cigna recognizes pharmacy revenue largely on cash-eligible service performance — but the gap is wide enough that a normalized DSO walk-back at 2024 would shave roughly $2.5B from CFO if the trend reverses.

The chart shows what the smoothness hides: 2024 carried $2.5B of equity-investment impairments and 2023 carried a $1.5B goodwill impairment on the planned Medicare Advantage divestiture, both of which were excluded from adjusted earnings. They are properly classified in GAAP, and the disclosures meet the "special items" definition the company has used since at least 2019. The forensic concern is not the exclusion — it is that "special items" averaged $1.16B pre-tax over 2023–2025, which is roughly 14% of pre-tax adjusted income; classifying that volume of charges as non-operating year after year qualifies as a recurring "non-recurring."

Cash Flow Quality

Cigna's cash conversion is genuinely strong in absolute terms — but a meaningful slice of that strength is working-capital-engineered, and the AR factoring facility is the swing factor.

Net income minus operating cash flow ran -$6.6B and -$6.9B in 2023 and 2024 — well outside the -$1.8B to -$2.0B range from 2021–2022 and the -$3.6B in 2025. In a sector with rising medical claims liabilities and growing pharmacy payables this is partially structural, but the 2023 MD&A explicitly calls out "acceleration of cash proceeds from the accounts receivable factoring facility" as one of four reasons CFO rose; the 2025 MD&A reverses that and flags "timing of settlements related to the accounts receivable factoring facility" as a CFO drag. Cigna does not separately disclose the size of the facility, the discount rate, or the off-balance-sheet receivables transferred — disclosures that under SEC FRM and ASU 2022-04 supplier-finance language would normally accompany a facility large enough to move CFO by $1B+ year over year.

Acquisition-adjusted free cash flow (CFO – capex – acquisitions) was $6.1B in 2025, down from $9.0B in 2023; the company stepped up bolt-on acquisitions including a $1.7B Shields Health Solutions investment funded partly by a $2.0B term loan in August 2025. Including the $4.9B HCSC sale proceeds, total cash inflow from divestitures is overstated — and the proceeds went largely to share repurchases ($3.6B in 2025), which preserves the capital-return narrative but does not validate underlying CFO durability.

The CFO test passes if you accept the structural working-capital build and the AR factoring tailwind as recurring. It fails if you regard the factoring facility as financing in substance — a treatment the SEC has questioned in other 10-K reviews and a posture short-sellers will likely take in any escalation.

Metric Hygiene

Cigna's non-GAAP framework is well-disclosed but heavily relied upon. The investor materials lead with adjusted EPS of $29.84 in 2025 versus GAAP EPS of $22.18, a 35% gap; in 2024 the gap was 125% ($27.33 adjusted vs $12.12 GAAP). The exclusions are conservative in form (intangible amortization, investment gains/losses, JV equity-method effects, special items) and the reconciliations are complete in the 10-K and proxy.

The cleanest metric-hygiene critique: Cigna characterizes "strategic optimization program" charges of $749M as a special item in 2025, after also calling 2023 charges of $252M for "organizational efficiency" non-recurring; integration costs from Express Scripts have been treated as special items in some form for the eighth consecutive year. The pattern is recurring. Investors should mentally pencil at least $300–$500M of pre-tax charges into "adjusted" earnings each year as run-rate, not as one-time, when underwriting forward EPS.

What to Underwrite Next

The forensic risk is not severe enough to be a thesis breaker, but it is severe enough to limit position size and require active monitoring. Treat the accounting risk as a 10-15% valuation haircut to fair value relative to a clean-control comparable, and require concrete risk-disconfirming events before relaxing.

Specific items to track:

• Ascent rebate litigation: Watch for class certification, motion-to-dismiss outcomes, and any 8-K Item 4.02 (non-reliance) related to PBM revenue disclosures. The Bernstein Litowitz suit (filed Feb 17, 2026) and the FTC-mandated Ascent redomicile are the highest-conviction red flags. A loss on motion-to-dismiss would force materially expanded related-party disclosure in 2026 10-K notes.
• AR factoring disclosure: Watch for explicit quantification of receivables sold without recourse, the discount rate, and the year-end balance under ASU 2022-04 supplier-finance principles applied to receivables sales (or under Item 303 SAB 11M-style disclosure). 2025 10-K Note text is the next reading.
• Adjusted-vs-GAAP gap normalization: A 2026 GAAP EPS that is closer to adjusted (say within 20%) would be a positive signal that the special-items pipeline is genuinely closing. The opposite — another year above 30% — keeps the metric-hygiene flag yellow.
• Reserve development direction: Favorable prior-year reserve development was $456M (2024) → $342M (2025). If 2026 development comes in below $200M or turns adverse, the historic reserve-release benefit to MCR will fade and 2024 medical-cost expectations may require restatement of the 2025 algorithm.
• Audit committee continuity and Critical Audit Matter language: The 2026 PwC audit report names IBNR as the only Critical Audit Matter. A new CAM — particularly anything pointing to revenue recognition, related-party transactions, or rebate accounting — would be the strongest internal accounting-side warning.

A signal that would downgrade the forensic grade to High (61–80) would be any one of: (i) an 8-K Item 4.02 non-reliance disclosure, (ii) PCAOB/SEC enforcement inquiry on rebate or revenue accounting, (iii) PwC change after 43 years of tenure, or (iv) a material weakness disclosure tied to claims data or related-party controls. A signal that would upgrade the grade to Watch would be: (i) Ascent litigation dismissed at the pleading stage, (ii) explicit AR-factoring quantification with no off-balance-sheet recourse, and (iii) one full year where adjusted-to-GAAP gap stays under 20%.

The accounting itself is sound and the auditor relationship is stable. The risk that needs underwriting is operational and presentational: how the PBM rebate model, the offshore Ascent vehicle, the working-capital factoring lever, and the smoothed adjusted-earnings narrative behave under regulatory and litigation pressure that is now actively in motion. For an institutional investor sizing a position, this is a "trim 15% on accounting overlay" or "require a wider margin of safety" call — not a "won't own" call. But it is also not the clean shop that a 43-year auditor tenure and a $5.96B GAAP shareholders' net income headline might initially suggest.